'Meaningful' glucose monitoring is encouraged.
JACKSONVILLE, Fla. -- Citing glycemic measurement as an essential component of care for all patients with diabetes, the American Association of Clinical Endocrinologists (AACE) last month announced the publication of its outpatient glucose monitoring consensus statement.
The statement provides detailed analyses to support precise recommendations for the type of system and frequency of use for either self-monitoring blood glucose (SMBG) therapy or continuous glucose monitoring (CGM) to reduce short- and long-term complications of diabetes.
While acknowledging challenges with glucose monitoring modalities --including accuracy and precision variances between different manufacturers' products, cost and access issues, and patient monitoring aptitude--the statement encourages "meaningful monitoring," individualized clinical management that is customized to each patient's preference and lifestyle and empowers patients to manage glucose levels to reduce complications, particularly hypoglycemia.
"Although glucose monitoring alone is not adequate to promote optimal diabetes management, it plays a necessary and crucial role in preventing or delaying the complications inherent with this disease," said Timothy Bailey, co-chair of the consensus statement writing committee. "In order to optimize the clinical management of diabetes, it is imperative that patients and health care professionals collaborate closely when adapting to glucose monitoring technology."
"This includes health professionals' education of patients regarding the interpretation and use of GM data to help modify behaviors, enhance their ability to self-adjust therapy, and help them decide when to seek medical assistance," added AACE president and writing committee cochair George Grunberger.
Meanwhile, LifeScan Canada, a division of Johnson & Johnson, introduced the OneTouch Verio Flex blood glucose meter last month.
For the nearly 3 million Canadians living with diabetes, self-monitoring of blood glucose is an integral part of managing blood glucose and overall diabetes management, says the company, noting that 50% of patients do not achieve the recommended targets set by their health care professionals.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||RX/Diabetes Care|
|Publication:||Chain Drug Review|
|Date:||Mar 14, 2016|
|Previous Article:||Report highlights the longevity, versatility of insulin therapy.|
|Next Article:||The diabetic foot is focus of treatment guidelines.|